Company completed Type C meeting with FDA, aligning on its plan to submit an sNDA; submission expected around end of 1Q25If approved, FILSPARI ...

CSL (ASX:CSL) has reported a net profit after tax of $2.01 billion for the six months to the ned of December 2024, up 7 per ...

Company completed Type C meeting with FDA, aligning on its plan to submit an sNDA; submission expected around end of 1Q25 If approved, FILSPARI could be the first and only approved medicine indicated ...

“CSL delivered a solid result for the first half of the 2025 financial year led by CSL Behring. Strong demand for many of our market-leading therapies has translated into sales growth, particularly in ...

A study showed notable differences in bone mineral density between children on steroids and those not on steroids, with 84% ...

A domestic industry may never be too small so long as the commercial product is 100% American-made according to the latest Federal Circuit opinion.

CEO Paul McKenzie announced a reaffirmation of guidance for fiscal 2025, targeting NPATA growth of 10% to 13%. He highlighted strong results from CSL Behring and growth in CSL Vifor, while ...

Q3 2024 Earnings Call Transcript February 10, 2025 Roivant Sciences Ltd. beats earnings expectations. Reported EPS is $0.23, expectations were $-0.24. Operator: Ladies and gentlemen, thank you for ...

It's not just milk, butter, cheese and yoghurt you need to avoid. Here's everything you need to know about preparing dairy-free food… There are many alternatives to dairy, and all these dishes ...